Selected article for: "adjusted hazard ratio and admission course"
Author: Aomar-Millán, Ismael Francisco; Salvatierra, Juan; Torres-Parejo, Úrsula; Faro-Miguez, Naya; Callejas-Rubio, José Luis; Ceballos-Torres, Ángel; Cruces-Moreno, María Teresa; Gómez-Jiménez, Francisco Javier; Hernández-Quero, José; Anguita-Santos, Francisco
Title: Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study
  • Cord-id: ogxquo5p
  • Document date: 2021_1_5
    • ID: ogxquo5p
    Snippet: INTRODUCTION: Little evidence appears to exist for the use of anakinra, a recombinant interleukin-1 receptor antagonist, after non-response to treatment with corticosteroids alone or combined with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammatory state. PATIENTS AND METHODS: A retrospective observational cohort study was carried out involving 143 patients with severe COVID-19 pneumonia and moderate hyperinflammation. They received standard therapy along with p
    Document: INTRODUCTION: Little evidence appears to exist for the use of anakinra, a recombinant interleukin-1 receptor antagonist, after non-response to treatment with corticosteroids alone or combined with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammatory state. PATIENTS AND METHODS: A retrospective observational cohort study was carried out involving 143 patients with severe COVID-19 pneumonia and moderate hyperinflammation. They received standard therapy along with pulses of methylprednisolone (group 1) or methylprednisolone plus tocilizumab (group 2), with the possibility of receiving anakinra (group 3) according to protocol. The aim of this study was to assess the role of anakinra in the clinical course (death, admission to the intensive care ward) during the first 60 days after the first corticosteroid pulse. Clinical, laboratory, and imaging characteristics as well as infectious complications were also analyzed. RESULTS: 74 patients (51.7%) in group 1, 59 (41.3%) patients in group 2, and 10 patients (7%) in group 3 were included. 8 patients (10.8%) in group 1 died, 6 (10.2%) in group 2, and 0 (0%) in group 3. After adjustment for age and clinical severity indices, treatment with anakinra was associated with a reduced risk of mortality (adjusted hazard ratio 0.518, 95% CI 0.265–0.910; p = 0.0437). Patients in group 3 had a lower mean CD4 count after 3 days of treatment. No patients in this group presented infectious complications. CONCLUSIONS: In patients with moderate hyperinflammatory state associated with severe COVID-19 pneumonia, treatment with anakinra after non-response to corticosteroids or corticosteroids plus tocilizumab therapy may be an option for the management of these patients and may improve their prognosis.

    Search related documents:
    Co phrase search for related documents
    • abdominal pain and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • abdominal pain and admission prior: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • abdominal pain and liver dysfunction: 1, 2, 3, 4
    • abdominal pain and lopinavir ritonavir: 1, 2, 3, 4
    • acute myocardial infarction and admission difference: 1, 2
    • acute myocardial infarction and admission prior: 1, 2, 3
    • acute myocardial infarction and liver dysfunction: 1
    • acute myocardial infarction and lopinavir ritonavir: 1
    • acute respiratory syndrome and adjust dose: 1
    • acute respiratory syndrome and admission anakinra: 1
    • acute respiratory syndrome and admission difference: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • acute respiratory syndrome and admission prior: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and admission treatment group: 1, 2, 3
    • acute respiratory syndrome and liver dysfunction: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and liver dysfunction severe sepsis: 1
    • acute respiratory syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • admission difference and liver dysfunction: 1